Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 24791224)

1.

DNA Aptamer Technology for Personalized Medicine.

Xing H, Hwang K, Li J, Torabi SF, Lu Y.

Curr Opin Chem Eng. 2014 May 1;4:79-87.

2.

Cell-specific aptamers and their conjugation with nanomaterials for targeted drug delivery.

Liao J, Liu B, Liu J, Zhang J, Chen K, Liu H.

Expert Opin Drug Deliv. 2015 Mar;12(3):493-506. doi: 10.1517/17425247.2015.966681. Epub 2014 Nov 28.

PMID:
25430795
3.

Aptamer-dendrimer bioconjugate: a nanotool for therapeutics, diagnosis, and imaging.

Pednekar PP, Jadhav KR, Kadam VJ.

Expert Opin Drug Deliv. 2012 Oct;9(10):1273-88. Epub 2012 Aug 16. Review.

PMID:
22897588
4.

Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine.

Xiang D, Shigdar S, Qiao G, Wang T, Kouzani AZ, Zhou SF, Kong L, Li Y, Pu C, Duan W.

Theranostics. 2015 Jan 1;5(1):23-42. doi: 10.7150/thno.10202. eCollection 2015. Review.

5.

Molecular aptamers for drug delivery.

Tan W, Wang H, Chen Y, Zhang X, Zhu H, Yang C, Yang R, Liu C.

Trends Biotechnol. 2011 Dec;29(12):634-40. doi: 10.1016/j.tibtech.2011.06.009. Epub 2011 Aug 6. Review.

6.

Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy.

Li X, Zhao Q, Qiu L.

J Control Release. 2013 Oct 28;171(2):152-62. doi: 10.1016/j.jconrel.2013.06.006. Epub 2013 Jun 15. Review.

PMID:
23777885
7.

Aptamers as imaging agents.

Gomes Sda R, Azéma L, Allard M, Toulmé JJ.

Expert Opin Med Diagn. 2010 Nov;4(6):511-8. doi: 10.1517/17530059.2010.516248. Epub 2010 Sep 27.

PMID:
23496229
8.

Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach.

Fang X, Tan W.

Acc Chem Res. 2010 Jan 19;43(1):48-57. doi: 10.1021/ar900101s.

9.

Oligonucleotide aptamers: new tools for targeted cancer therapy.

Sun H, Zhu X, Lu PY, Rosato RR, Tan W, Zu Y.

Mol Ther Nucleic Acids. 2014 Aug 5;3:e182. doi: 10.1038/mtna.2014.32.

10.

Aptamers: active targeting ligands for cancer diagnosis and therapy.

Wu X, Chen J, Wu M, Zhao JX.

Theranostics. 2015 Jan 20;5(4):322-44. doi: 10.7150/thno.10257. eCollection 2015.

11.

Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma.

Shum KT, Zhou J, Rossi JJ.

J Cancer Ther. 2013 Jun 1;4(4):872-890.

12.

Screening of aptamers on microfluidic systems for clinical applications.

Weng CH, Huang CJ, Lee GB.

Sensors (Basel). 2012;12(7):9514-29. Epub 2012 Jul 11. Review.

13.

Peptide- and aptamer-functionalized nanovectors for targeted delivery of therapeutics.

Pangburn TO, Petersen MA, Waybrant B, Adil MM, Kokkoli E.

J Biomech Eng. 2009 Jul;131(7):074005. doi: 10.1115/1.3160763. Review.

PMID:
19655996
14.

Nanotechnology: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2006;6(19):1-43. Epub 2006 Nov 1.

15.

Aptamer-based biosensors for biomedical diagnostics.

Zhou W, Huang PJ, Ding J, Liu J.

Analyst. 2014 Jun 7;139(11):2627-40. doi: 10.1039/c4an00132j.

PMID:
24733714
16.

Generating Aptamers by Cell-SELEX for Applications in Molecular Medicine.

Ye M, Hu J, Peng M, Liu J, Liu J, Liu H, Zhao X, Tan W.

Int J Mol Sci. 2012;13(3):3341-53. doi: 10.3390/ijms13033341. Epub 2012 Mar 12.

17.

Chimeric aptamers in cancer cell-targeted drug delivery.

Kanwar JR, Roy K, Kanwar RK.

Crit Rev Biochem Mol Biol. 2011 Dec;46(6):459-77. doi: 10.3109/10409238.2011.614592. Epub 2011 Sep 28. Review.

18.

Nucleic acid aptamer-mediated drug delivery for targeted cancer therapy.

Zhu H, Li J, Zhang XB, Ye M, Tan W.

ChemMedChem. 2015 Jan;10(1):39-45. doi: 10.1002/cmdc.201402312. Epub 2014 Oct 2.

PMID:
25277749
19.

Tumor-targeted drug delivery with aptamers.

Zhang Y, Hong H, Cai W.

Curr Med Chem. 2011;18(27):4185-94. Review.

20.

Aptamer applications for targeted cancer therapy.

Barbas AS, Mi J, Clary BM, White RR.

Future Oncol. 2010 Jul;6(7):1117-26. doi: 10.2217/fon.10.67. Review.

PMID:
20624124
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk